Prestige Consumer Healthcare Inc. (PBH) earnings date, results and what the price requires
NYSE · SEC CIK 0001295947 · SEC filings checked Oct 17, 2026
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 6, 2026 | $265.7M | $29.2M | $0.61 | Filing |
| Mar 31, 2026 | May 13, 2026 | $281.6M | $53.9M | $1.13 | Filing |
| Dec 31, 2025 | Feb 5, 2026 | $283.4M | $46.7M | $0.97 | Filing |
| Sep 30, 2025 | Nov 6, 2025 | $274.1M | $42.2M | $0.86 | Filing |
| Jun 30, 2025 | Aug 7, 2025 | $249.5M | $47.5M | $0.95 | Filing |
| Mar 31, 2025 | May 8, 2025 | $296.5M | $50.1M | $1.00 | Filing |
| Dec 31, 2024 | Feb 6, 2025 | $290.3M | $61.0M | $1.22 | Filing |
| Sep 30, 2024 | Nov 7, 2024 | $283.8M | $54.4M | $1.09 | Filing |
What would Prestige Consumer Healthcare Inc. have to report for its valuation to change?
At $49.92, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about 3.6% a year, to $4.27. On that path the next quarter needs diluted EPS near $0.89, against $0.86 in the quarter ended Sep 30, 2025.
Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.
| Result | Original | Yours |
|---|---|---|
| Required EPS growth / year | 3.6% | 3.6% |
| EPS needed in final year | $4.27 | $4.27 |
Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.
Prepare for earnings across my investments — $399/month
Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. PBH goes in with your buy-or-wait comparison and assumptions preserved.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.